Amgen (AMGN +0.1%) says the FDA has halted all pediatric clinical trials of Sensipar after a...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN +0.1%) says the FDA has halted all pediatric clinical trials of Sensipar after a reported death of a 14-year-old patient taking part in a study of the drug used to lower calcium levels in the blood. AMGN however, says that there's no conclusion on Sensipar's role in the death as outlined by the FDA, and it was still working with the agency on the drug's development.